Drugs / mRNA-based COVID-19 vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05442684 Comparator | Nov 2022 → Mar 2023 | COVID-19 | CanSino Biologics Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-based COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05442684 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based COVID-19 vaccine” NCT05442684 ↗ |